HKBU Centre for Chinese Herbal Medicine Drug Development and CR Jiangzhong sign strategic collaboration agreement

Photo source: 人民资讯

The Centre for Chinese Herbal Medicine Drug Development (the Centre) of HKBU and CR Jiangzhong, a subsidiary of China Resources (Holdings) Co., Ltd. (CR Group) signed a strategic collaboration agreement on February 2, 2024 (Friday) at Nanchang, the capital of Jiangxi province of China.

The collaboration agreement sets out the focus of the comprehensive cooperation between the two parties in a variety of areas, including the construction of a demonstration platform for Chinese medicine industry-academia-research, technology and product research and development, transformation of scientific and technological achievements, joint application for innovative products, and collaborative talent training. During the meeting, the two parties exchanged ideas on the research and development of novel Chinese medicine drugs for the human digestive system. 

The Vice-President (Research and Development) of HKBU, Professor Lyu Aiping, expressed that the establishment of a joint technology industry consortium plays a positive role in enhancing the targeted nature of research and development, in facilitating technological exchange and collaboration, and in the development, industrialisation and marketisation of new Chinese medicine products. The innovative development of Chinese medicine should fully utilise interdisciplinary technologies from disciplines such as mathematics, physics, bioinformatics, and artificial intelligence to promote the formation of new models for future medical development. Professor Bian Zhaoxiang, Associate Vice-President (Chinese Medicine Development) was also one of the representatives of HKBU attending the meeting.

The Chairman of CR Jiangzhong Mr Liu Weiquan stated that CR Jiangzhong consistently implements the initiatives of CR group and actively supports Hong Kong's technological innovation and integration into the national development plan. This strategic cooperation will be driven by impact creation. Fully leveraging CR Jiangzhong's scientific and creative resources, this cooperation will address practical problems through research and development innovations and provide strong momentum for the latest creation of Chinese medicine products at CR Jiangzhong.

Funded by Innovation and Technology Commission (ITC) of the HKSAR Government, the Centre was established in September 2020 to enhance the quality of pre-clinical and clinical Chinese medicine research and transform the results into pharmaceutical products for international markets.